Join to view full profile
1211 Fish Hatchery RdMadison, WI 53715
Phone+1 608-252-8000
Fax+1 608-410-2905
Dr. Frontiera is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 1983 - 1986
University of California (San Francisco)/FresnoResidency, Internal Medicine, 1980 - 1983
University of Kansas School of MedicineClass of 1980
Certifications & Licensure
CA State Medical License Current
WI State Medical License 1986 - 2027
CO State Medical License 1983 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- 24 citationsA randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert C. Whorf, Mark Keaton
Clinical Breast Cancer. 2011-08-01 - 261 citationsPhase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089Daniel G. Haller, Paul J. Catalano, John S. Macdonald, Mark Allen O'Rourke, Michael S. Frontiera
Journal of Clinical Oncology. 2005-12-01 - 6 citationsA phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group.Janice P. Dutcher, T Leong, A Z Makary, John M. Bennett, M Frontiera
Leukemia. 1995-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: